Pfizer Limited (PFIZER) - Total Assets
Based on the latest financial reports, Pfizer Limited (PFIZER) holds total assets worth Rs46.06 Billion INR (≈ $498.07 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of Pfizer Limited for net asset value and shareholders' equity analysis.
Pfizer Limited - Total Assets Trend (2005–2025)
This chart illustrates how Pfizer Limited's total assets have evolved over time, based on quarterly financial data.
Pfizer Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Pfizer Limited's total assets of Rs46.06 Billion consist of 71.5% current assets and 28.5% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs4.93 Billion | 10.5% |
| Accounts Receivable | Rs1.93 Billion | 3.9% |
| Inventory | Rs4.76 Billion | 9.7% |
| Property, Plant & Equipment | Rs1.79 Billion | 3.7% |
| Intangible Assets | Rs243.10 Million | 0.5% |
| Goodwill | Rs5.27 Billion | 10.7% |
Asset Composition Trend (2005–2025)
This chart illustrates how Pfizer Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Pfizer Limited.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Pfizer Limited's current assets represent 71.5% of total assets in 2025, a decrease from 72.8% in 2005.
- Cash Position: Cash and equivalents constituted 10.5% of total assets in 2025, down from 30.9% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, a decrease from 26.0% in 2005.
- Asset Diversification: The largest asset category is goodwill at 10.7% of total assets.
Pfizer Limited Competitors by Total Assets
Key competitors of Pfizer Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$208.73 Billion |
|
CSPC Pharmaceutical Group Limited
F:CVG
|
Germany | €46.00 Billion |
|
Aurora Optoelectronics Co Ltd
SHG:600666
|
China | CN¥1.60 Billion |
|
Shandong Keyuan Pharmaceutical Co. Ltd. A
SHE:301281
|
China | CN¥1.60 Billion |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3
|
Brazil | R$3.83 Billion |
|
Pfizer Inc
NYSE:PFE
|
USA | $208.73 Billion |
|
Merck & Company Inc
NYSE:MRK
|
USA | $129.55 Billion |
|
Firebrick Pharma Ltd
AU:FRE
|
Australia | AU$1.83 Million |
Pfizer Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.38 | 5.00 | 2.31 |
| Quick Ratio | 4.61 | 4.25 | 1.76 |
| Cash Ratio | 4.19 | 3.77 | 0.00 |
| Working Capital | Rs28.31 Billion | Rs24.18 Billion | Rs10.01 Billion |
Pfizer Limited - Advanced Valuation Insights
This section examines the relationship between Pfizer Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.86 |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | 16.1% |
| Total Assets | Rs49.11 Billion |
| Market Capitalization | $2.33 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Pfizer Limited's assets below their book value (0.05x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Pfizer Limited's assets grew by 16.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Pfizer Limited (2005–2025)
The table below shows the annual total assets of Pfizer Limited from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | Rs49.11 Billion ≈ $531.12 Million |
+16.14% |
| 2024-03-31 | Rs42.29 Billion ≈ $457.33 Million |
+5.70% |
| 2023-03-31 | Rs40.01 Billion ≈ $432.66 Million |
+2.57% |
| 2022-03-31 | Rs39.01 Billion ≈ $421.83 Million |
+19.43% |
| 2021-03-31 | Rs32.66 Billion ≈ $353.19 Million |
-25.87% |
| 2020-03-31 | Rs44.05 Billion ≈ $476.43 Million |
+11.81% |
| 2019-03-31 | Rs39.40 Billion ≈ $426.09 Million |
+6.78% |
| 2018-03-31 | Rs36.90 Billion ≈ $399.06 Million |
+12.82% |
| 2017-03-31 | Rs32.71 Billion ≈ $353.71 Million |
+12.25% |
| 2016-03-31 | Rs29.14 Billion ≈ $315.11 Million |
+11.57% |
| 2015-03-31 | Rs26.12 Billion ≈ $282.43 Million |
+182.53% |
| 2014-03-31 | Rs9.24 Billion ≈ $99.96 Million |
-55.12% |
| 2013-03-31 | Rs20.60 Billion ≈ $222.73 Million |
+30.64% |
| 2012-03-31 | Rs15.76 Billion ≈ $170.49 Million |
+13.72% |
| 2011-03-31 | Rs13.86 Billion ≈ $149.92 Million |
+15.20% |
| 2010-03-31 | Rs12.03 Billion ≈ $130.14 Million |
+9.63% |
| 2009-03-31 | Rs10.98 Billion ≈ $118.71 Million |
+26.53% |
| 2008-03-31 | Rs8.67 Billion ≈ $93.81 Million |
+34.18% |
| 2007-03-31 | Rs6.47 Billion ≈ $69.92 Million |
+12.23% |
| 2006-03-31 | Rs5.76 Billion ≈ $62.30 Million |
+10.32% |
| 2005-03-31 | Rs5.22 Billion ≈ $56.47 Million |
-- |
About Pfizer Limited
Pfizer Limited engages in manufacturing, marketing, trading, and distribution of pharmaceutical products in India and internationally. It offers its products in various therapeutic areas, including neuro/CNS, hormones, cardiovascular, haemophilia, anti-infectives, gynecology, pain/analgesics, orthopedic, oncology, urology, anti-parasitic, gastrointestinal, vaccines, and respiratory, as well as vi… Read more